Market Overview

UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

Share:
Related IMGN
ImmunoGen's IMGN529 for B-Cell Malignancies Demonstrates Synergistic Activity with Rituximab in Preclinical Models of Non-Hodgkin Lymphoma
16 Biotech Stocks Moving Off The ASCO Conference

Oppenheimer downgraded ImmunoGen (NASDAQ: IMGN) from Outperform to Perform and maintained a $14.00 price target.

Oppenheimer noted, "We are downgrading IMGN to Perform from Outperform and maintaining our $14 price target, as we believe the success of T-DM1 is now fully priced into the stock. We are warming to IMGN901 and will watch the NORTH study as it will likely be the next driver of IMGN that could move us off the sidelines. A NORTH update is expected 2H13. With the launch of T-DM1, as with any drug launch, initial Street expectations may be adjusted. A post-launch pullback in IMGN into low teens may also cause us to revisit our rating."

ImmunoGen closed at $15.04 on Friday.

Latest Ratings for IMGN

DateFirmActionFromTo
Jun 2015Morgan StanleyUpgradesUnderweightEqual-weight
May 2015Credit SuisseAssumesNeutral
Mar 2015Cantor FitzgeraldUpgradesHoldBuy

View More Analyst Ratings for IMGN
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (IMGN)

Get Benzinga's Newsletters